Otros artículos de Pietro Luigi Fagiolino Sabbatani
Vázquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. Int J Clin Pharmacol Ther 46:140-145, 2008.
Fagiolino P, González N, Vázquez M, Eiraldi R. Itraconazole bioequivalence revisited: influence of gender on highly variable drugs. Open Drug Metab J 1:7-13, 2007.
Fagiolino P, Vázquez M, Olano I, Delfino A. Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. J Epilepsy Clin Neurophysiol 12:13-16, 2006.
Fagiolino P, Eiraldi R, Vázquez M. The influence of cardiovascular physiology on dose / pharmacokinetic and pharmacokinetic / pharmacodynamic relationships. Clin Pharmacokinet 45:433-448, 2006.
Fagiolino P, Eiraldi R, Vázquez M. Intercambiabilidad de medicamentos. Bioequivalencia y equivalencia terapéutica. Acta Farm Bonaerense 24:179-89, 2005).
Fagiolino P. Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence. Eur J Drug Metab Pharmacokinet 29:43-49, 2004.
Fagiolino P, Wilson F, Samaniego E, Vázquez M. In vitro approach to study the influence of the cardiac output distribution on drug concentration. Eur J Drug Metab Pharmacokinet 28:147-153, 2003.
Olano I, Vázquez M, Fagiolino P. Chronopharmacokinetics of carbamazepine and its metabolite 10,11-epoxide. J Pharm Clin 17:153-156, 1998.
Vázquez M, Fagiolino P, De Nucci G, Parrillo S, Piñeyro A. Post-prandial reabsorption of paracetamol. Eur J Drug Metab Pharmacokinet, Special Issue:177-183, 1993.
Savio E, Fagiolino P, Vázquez M, León A. Bioavailability of a phenytoin W/O emulsion in humans. STP Pharma Sci 2:415-419, 1992.
Para comunicarse con Pietro Luigi Fagiolino Sabbatani mencionar a SIIC como
referencia:
pfagioli@fq.edu.uy
Autor invitado
4 de diciembre, 2008
Descripción aprobada
24 de febrero, 2009
Reedición siicsalud
7 de junio, 2021